Members with cardiac conditions may like to consider registering with CredibleMeds to be kept up to date with any changes to the QT drugs to avoid list https://crediblemeds.org/everyone/.
We have recently received the following message through CredibleMeds:
April 29, 2024
Re: Changes to the QTdrugs List and List of Drugs to Avoid in cLQTS
Dear CredibleMeds Registrants:
AZCERT’s Scientific Review Committee for the QTdrugs List has found substantial evidence that the following medications are associated with the development of QT prolongation but lack convincing evidence of torsades de pointes (TdP):
- Moclobemide (antidepressant)
- Gepirone (antidepressant)
- Motixafortide (Multiple myeloma therapy)
- Givinostat (Duchenne muscular dystrophy therapy)
- Isoflurane (general anesthetic)
Therefore, these medications have been added to the Possible Risk of TdP category (PR) and the List of Drugs to Avoid in patients with Congenital Long QT Syndrome (DTA List).
Also, the Committee found substantial evidence that Ivabradine (antianginal drug), previously in the Conditional Risk of TdP category, is associated with QT prolongation and TdP when used as directed. Therefore, Ivabradine has been changed to the Known Risk of TdP category. In addition, Quizartinib (leukemia therapy) was added to the Known Risk of TdP category on February 5, 2024.
